These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 6143506)

  • 1. Methylphenidate challenge as a predictor of relapse in schizophrenia.
    Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
    Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical predictors of relapse following neuroleptic withdrawal.
    Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
    Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of relapse in schizophrenia.
    Lieberman JA; Kane JM; Sarantakos S; Gadaleta D; Woerner M; Alvir J; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1987 Jul; 44(7):597-603. PubMed ID: 2886110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H; Hunt JI; Vitiello B; Simpson GM
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
    Wistedt B; Palmstierna T
    J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
    Lieberman JA; Alvir J; Geisler S; Ramos-Lorenzi J; Woerner M; Novacenko H; Cooper T; Kane JM
    Neuropsychopharmacology; 1994 Oct; 11(2):107-18. PubMed ID: 7840862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-dopa challenge and relapse in schizophrenia.
    Davidson M; Keefe RS; Mohs RC; Siever LJ; Losonczy MF; Horvath TB; Davis KL
    Am J Psychiatry; 1987 Jul; 144(7):934-8. PubMed ID: 2886063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mood responses of remitted schizophrenics to methylphenidate infusion.
    Robinson D; Mayerhoff D; Alvir J; Cooper T; Lieberman J
    Psychopharmacology (Berl); 1991; 105(2):247-52. PubMed ID: 1796130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
    Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
    Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
    Leblanc G; Cormier H; Gagné MA; Vaillancourt S
    Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
    Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
    Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of antipsychotic effects of neuroleptic drugs.
    Keck PE; Cohen BM; Baldessarini RJ; McElroy SL
    Am J Psychiatry; 1989 Oct; 146(10):1289-92. PubMed ID: 2571305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
    Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
    Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
    Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
    Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.